UCM General Financial Conflict of Interest Disclosure
This Financial Conflict of Interest Disclosure is necessary for UCM to maintain federal compliance with PHS regulations set forth in 45 CFR Part 94 (https://www.ecfr.gov/current/title-45/subtitle-A/subchapter-A/part-94) and 42 CFR Part 50, Subpart F (https://www.ecfr.gov/current/title-42/chapter-I/subchapter-D/part-50/subpart-F). These regulations are in place to avoid possible bias as a result of any conflicting financial interest by Investigators/Project Directors. Additionally, this disclosure is designed to protect research subjects, ensuring they will not be jeopardized by conflicting financial interests of Investigators. (Please see below for definitions of Significant Financial Interest.) The information requested is required under the Financial Disclosure Policy of the Public Health Services (PHS), the National Science Foundation (NSF), the Food and Drug Administration (FDA) and other public and private funding sources.
BEFORE COMPLETING THIS DISCLOSURE, 42 CFR Part 50 requires UCM to "inform each Investigator of the Institution's policy on financial conflicts of interest, the Investigator's responsibilities regarding disclosure of significant financial interests, and of these regulations, and require each Investigator to complete training regarding the same prior to engaging in research." Therefore, Investigators/Project Directors are required to successfully pass the CITI Program's Financial Conflicts of Interest Course. (https://www.citiprogram.org). This course will need to be successfully completed once every four years.
This Financial Conflict of Interest Disclosure must be certified at time of application, at time of award, and annually thereafter, throughout the lifetime of sponsored program activity at UCM. Investigators must also submit and certify a new disclosure within 30 days of the development and/or termination of a financial conflict.
_____________________
[OSPRI Only: 5/7/24]